Oncorena has announced that Börje Haraldsson has joined the management team as Chief Scientific Officer.
Professor Haraldsson, is one of the founders of Oncorena. Being a world leader in clinical and experimental renal research, he will bring a wealth of clinical experience and competence to the company, states the company.
“It is truly a great pleasure to welcome Börje Haraldsson to our team. I am proud that he has accepted the new and important role as Chief Scientific Officer at Oncorena. Börje is a purpose-driven, compassionate, and constructive leader well suited to lead our research to best serve patients with advanced renal cancer. It is our hope that the results from our clinical study will be of great benefit to patients in the future,” says Lars Grundemar, Chief Executive Officer of Oncorena.
Most recently, Professor Börje Haraldsson held a tenure as Global Program Head at Novartis in Basel, Switzerland, where he during seven years initiated and lead high-profile development projects in nephrology, transplantation, and rheumatology. Before he moved to Switzerland, the Swedish Research Council supported his research with grants for 25 years without interruption.
He has also been the Chair of Nephrology for 15 years combined with chief consultantship at Sahlgrenska University Hospital in Gothenburg. Furthermore, at the University of Gothenburg, he also served as Vice Dean for five years and at the Board of Directors for two years.
Photo of Börje Haraldsson: GU Ventures